Shree Ganesh Remedies Ltd

Shree Ganesh Rem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Shree Ganesh Remedies Ltd

₹ 648 -0.15%
27 May - close price
ganeshremedies.com BSE: 540737
About

Incorporated in 1995, Shree Ganesh Remedies Ltd is a manufacturer of Pharmaceutical Drug Intermediates for API & Fine Chemicals[1]

Key Points

Business Overview:[1]
SGRL is an ISO 14001 certified complex chemical manufacturer, specialising in pharmaceutical intermediates and speciality chemicals.

Website BSE
  • Market Cap ₹ 832 Cr.
  • Current Price ₹ 648
  • High / Low ₹ 660 / 381
  • Stock P/E 46.8
  • Book Value ₹ 127
  • Dividend Yield 0.00 %
  • ROCE 14.6 %
  • ROE 11.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company's median sales growth is 29.5% of last 10 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Debtor days have increased from 80.8 to 109 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
29.61 26.72 33.42 27.97 37.33 24.78 32.33 27.05 24.43 24.67 30.32 21.11 33.20
20.97 20.16 24.19 19.76 20.39 16.65 21.02 17.14 14.55 17.37 20.70 14.38 21.82
Operating Profit 8.64 6.56 9.23 8.21 16.94 8.13 11.31 9.91 9.88 7.30 9.62 6.73 11.38
OPM % 29.18% 24.55% 27.62% 29.35% 45.38% 32.81% 34.98% 36.64% 40.44% 29.59% 31.73% 31.88% 34.28%
0.34 0.73 0.80 1.11 1.32 0.54 0.19 0.71 2.29 0.66 0.69 0.66 1.02
Interest 0.08 0.01 0.01 0.02 0.15 0.32 0.43 0.38 0.96 0.94 1.01 0.74 0.88
Depreciation 1.03 1.02 1.41 1.88 1.86 2.02 2.42 2.70 2.42 2.42 2.59 2.67 2.80
Profit before tax 7.87 6.26 8.61 7.42 16.25 6.33 8.65 7.54 8.79 4.60 6.71 3.98 8.72
Tax % 14.99% 27.64% 23.81% 35.31% 22.46% 26.70% 25.78% 27.85% 24.80% 25.00% 26.23% 22.36% 28.10%
6.70 4.54 6.55 4.80 12.59 4.65 6.42 5.43 6.60 3.45 4.96 3.10 6.27
EPS in Rs 5.23 3.55 5.12 3.75 9.84 3.62 5.00 4.23 5.14 2.69 3.86 2.41 4.88
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
16 16 20 27 35 58 49 71 91 126 109 109
14 14 16 22 26 47 35 53 68 84 69 74
Operating Profit 2 2 4 5 9 11 14 18 23 42 39 35
OPM % 13% 12% 21% 19% 25% 19% 28% 25% 26% 33% 36% 32%
0 0 0 2 1 4 2 4 1 3 4 3
Interest 0 0 0 0 0 0 0 0 0 1 2 4
Depreciation 1 1 1 1 1 2 3 3 4 6 10 10
Profit before tax 2 2 4 6 9 13 13 18 20 38 31 24
Tax % 33% 34% 33% 28% 28% 24% 25% 26% 25% 26% 26% 26%
1 1 3 5 6 10 10 13 15 28 23 18
EPS in Rs 7.94 6.75 16.50 3.66 4.88 7.52 7.62 10.47 11.86 21.97 18.00 13.84
Dividend Payout % 0% 0% 0% 19% 18% 14% 18% 4% 2% 2% 0% 0%
Compounded Sales Growth
10 Years: 22%
5 Years: 17%
3 Years: 6%
TTM: 1%
Compounded Profit Growth
10 Years: 32%
5 Years: 13%
3 Years: 5%
TTM: -22%
Stock Price CAGR
10 Years: %
5 Years: 18%
3 Years: 29%
1 Year: 6%
Return on Equity
10 Years: 19%
5 Years: 19%
3 Years: 17%
Last Year: 12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 1 1 1 9 9 9 10 12 13 13 13 13
Reserves 12 13 15 20 25 33 40 50 75 109 132 150
0 0 0 2 1 2 0 0 33 36 38 31
2 2 5 5 7 8 10 15 18 12 8 14
Total Liabilities 15 16 21 36 41 52 61 77 138 171 192 208
4 4 4 6 14 16 19 27 58 81 95 105
CWIP 0 0 0 0 0 0 2 3 15 17 9 12
Investments 0 0 0 4 4 7 3 0 0 5 18 13
11 11 17 25 23 29 37 47 64 69 70 78
Total Assets 15 16 21 36 41 52 61 77 138 171 192 208

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-1 -2 2 -1 -5 4 3 13 17 30 31 24
1 1 0 -3 -0 -3 -1 -12 -51 -33 -35 -10
-0 -0 -0 8 -0 -0 -1 -1 39 10 -1 -12
Net Cash Flow -1 -0 2 4 -5 1 2 0 5 7 -6 2
Free Cash Flow -1 -2 2 -0 -5 4 3 -2 -32 -1 7 7
CFO/OP -58% -79% 44% -18% -60% 35% 24% 75% 73% 92% 104% 82%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 93 133 136 78 101 104 99 94 112 59 75 109
Inventory Days 132 130 103 102 125 56 206 132 138 156 223 209
Days Payable 43 32 90 43 75 39 101 92 118 51 61 82
Cash Conversion Cycle 183 232 149 137 151 120 205 134 133 164 238 236
Working Capital Days 160 202 172 128 145 102 158 133 122 89 111 169
ROCE % 16% 12% 26% 27% 27% 33% 28% 33% 22% 28% 19% 15%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Dec 2025
Export Contribution to Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
Capacity Utilization
%
Installed Capacity
MT p.a.
Production Volume
MT p.a.
Core Product Count
Units
Number of Functional Blocks (Unit 1)
Units
Geographic Reach (Export Countries)
Countries
R&D Team Strength
Headcount
Top 10 Molecule Revenue Concentration
%
Total Reactor Capacity (Pilot Plant)
Litres

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
69.34% 69.33% 69.33% 69.33% 69.33% 70.49% 72.80% 72.80% 72.80% 72.80% 72.80% 72.83%
0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00%
30.66% 30.67% 30.66% 30.67% 30.66% 29.50% 27.19% 27.20% 27.20% 27.19% 27.20% 27.16%
No. of Shareholders 6,4077,3307,5187,0497,1868,5088,6958,9789,1668,7528,4428,058

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls